Importantly, a lower PAX7 target gene score associates with FSHD clinical outcome correlating with fatty replacement of muscle (T1 positivity on MRI – Fig 3) independently of DUX4 target gene activation. This evidence concerns the gene PAX7 and Facioscapulohumeral dystrophy.